Literature DB >> 25895710

Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma.

Mia Dahl Sørensen1, Sigurd Fosmark, Sofie Hellwege, Dagmar Beier, Bjarne Winther Kristensen, Christoph Patrick Beier.   

Abstract

Glioblastoma remains a tumor with a dismal prognosis because of failure of current treatment. Glioblastoma cells with stem cell (GSC) properties survive chemotherapy and give rise to tumor recurrences that invariably result in the death of the patients. Here we summarize the current knowledge on chemoresistance of malignant glioma with a strong focus on GSC. Chemoresistant GSC are the most likely cause of tumor recurrence, but it remains controversial if GSC and under which conditions GSC are more chemoresistant than non-GSC within the tumor. Regardless of this uncertainty, the chemoresistance varies and it is mainly mediated by intrinsic factors. O6-methyl-guanidine methyltransferase (MGMT) remains the most potent mediator of chemoresistance, but disturbed mismatch repair system and multidrug resistance proteins contribute substantially. However, the intrinsic resistance by MGMT expression is regulated by extrinsic factors like hypoxia increasing MGMT expression and thereby resistance to alkylating chemotherapy. The search of new biomarkers helping to predict the tumor response to chemotherapy is ongoing and will complement the already known markers like MGMT.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25895710     DOI: 10.1007/978-3-319-16537-0_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  20 in total

1.  Inhibition of monocarboxylate transporter 1 suppresses the proliferation of glioblastoma stem cells.

Authors:  Tetsuya Takada; Kazuyuki Takata; Eishi Ashihara
Journal:  J Physiol Sci       Date:  2016-02-22       Impact factor: 2.781

Review 2.  3D bioprinting of glioblastoma models.

Authors:  Carolina Parra-Cantu; Wanlu Li; Alfredo Quiñones-Hinojosa; Yu Shrike Zhang
Journal:  J 3D Print Med       Date:  2020-10-28

Review 3.  The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.

Authors:  Brenda Auffinger; Drew Spencer; Peter Pytel; Atique U Ahmed; Maciej S Lesniak
Journal:  Expert Rev Neurother       Date:  2015-05-31       Impact factor: 4.618

Review 4.  Resistance to Cell Death and Its Modulation in Cancer Stem Cells.

Authors:  Ahmad R Safa
Journal:  Crit Rev Oncog       Date:  2016

5.  MiR-146b-5p overexpression attenuates stemness and radioresistance of glioma stem cells by targeting HuR/lincRNA-p21/β-catenin pathway.

Authors:  Wei Yang; Hongquan Yu; Yueming Shen; Yingying Liu; Zhanshan Yang; Ting Sun
Journal:  Oncotarget       Date:  2016-07-05

6.  Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.

Authors:  Yun Wang; Nanxin Huang; Hongli Li; Shubao Liu; Xianjun Chen; Shichang Yu; Nan Wu; Xiu-Wu Bian; Hai-Ying Shen; Chengren Li; Lan Xiao
Journal:  Oncotarget       Date:  2017-06-06

Review 7.  Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma.

Authors:  Laura Annovazzi; Marta Mellai; Davide Schiffer
Journal:  Cancers (Basel)       Date:  2017-05-26       Impact factor: 6.639

8.  The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches.

Authors:  Marco Mineo; Franz Ricklefs; Arun K Rooj; Shawn M Lyons; Pavel Ivanov; Khairul I Ansari; Ichiro Nakano; E Antonio Chiocca; Jakub Godlewski; Agnieszka Bronisz
Journal:  Cell Rep       Date:  2016-06-02       Impact factor: 9.423

9.  NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.

Authors:  Antonio Lucena-Cacace; Daniel Otero-Albiol; Manuel P Jiménez-García; Javier Peinado-Serrano; Amancio Carnero
Journal:  Oncotarget       Date:  2017-08-28

10.  Glioblastoma and glioblastoma stem cells are dependent on functional MTH1.

Authors:  Linda Pudelko; Pegah Rouhi; Kumar Sanjiv; Helge Gad; Christina Kalderén; Andreas Höglund; Massimo Squatrito; Alberto J Schuhmacher; Steven Edwards; Daniel Hägerstrand; Ulrika Warpman Berglund; Thomas Helleday; Lars Bräutigam
Journal:  Oncotarget       Date:  2017-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.